Phase 1 trial of poly (lactide-co-glycolide) (PLG) nanoparticles encapsulating antitubercular drugs (isoniazid, rifmapicin, pyrazinamide and ethambutol).

Trial Profile

Phase 1 trial of poly (lactide-co-glycolide) (PLG) nanoparticles encapsulating antitubercular drugs (isoniazid, rifmapicin, pyrazinamide and ethambutol).

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Rifampicin/isoniazid/pyrazinamide/ethambutol (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top